Stem cell-based therapies for brain injuries, such as traumatic brain injury (TBI), are a promising approach for clinical trials. However, technical hurdles such as invasive cell delivery and tracking with low transplantation efficiency remain challenges in translational stem-based therapy. This article describes an emerging technique for stem cell labeling and tracking based on the labeling of the mesenchymal stem cells (MSCs) with superparamagnetic iron oxide (SPIO) nanoparticles, as well as intranasal delivery of the labeled MSCs. These nanoparticles are fluorescein isothiocyanate (FITC)-embedded and safe to label the MSCs, which are subsequently delivered to the brains of TBI-induced mice by the intranasal route. They are then tracked non-invasively in vivo by real-time magnetic resonance imaging (MRI). Important advantages of this technique that combines SPIO for cell labeling and intranasal delivery include (1) non-invasive, in vivo MSC tracking after delivery for long tracking periods, (2) the possibility of multiple dosing regimens due to the non-invasive route of MSC delivery, and (3) possible applications to humans, owing to the safety of SPIO, non-invasive nature of the cell-tracking method by MRI, and route of administration.

Video Link

The video component of this article can be found at https://www.jove.com/video/60450/

Introduction

Mesenchymal stem cells (MSC) are attractive candidates for stem cell-based therapies in treatments of central nervous system (CNS) disorders and injuries in humans. Moreover, MSCs have been used as a vehicle for the delivery of therapeutic proteins at injury sites. In recent years, promising innovations have been developed to establish 1) novel routes of cell delivery and 2) cell tracking for stem cell-based therapies of CNS disorders. The intranasal delivery of stem cells into the brain depends on the ability of cells to bypass the cribriform plate and enter the olfactory bulb partially via a parenchymal route. The combination of intranasal delivery and the labeling of MSCs with superparamagnetic iron oxide (SPIO) nanoparticles represents a promising approach for clinical applications of MSCs in treating CNS disorders, since SPIO nanoparticles are safe probes for magnetic resonance imaging (MRI) and allow non-invasive sensitive longitudinal tracking of MSCs post-delivery by MRI. Furthermore, intranasal delivery is a safe and non-invasive route that allows repeated administration within a short period of time.

This article describes a highly sensitive and non-invasive technique for tracking MSCs in vivo post-intranasal delivery in a mouse model of traumatic brain injury (TBI), which employs SPIO-labeled cells and MRI. One important advantage of the SPIO labeling is the sensitive detection of SPIO in tissue by MRI, which makes it possible to track cells efficiently and non-invasively. The SPIO nanoparticles used here are commercially available and tagged with a fluorescein isothiocyanate (FITC) fluorophore, which allows for the detection of SPIO in tissue without immunostaining or additional processing. Furthermore, it is possible to perform longitudinal real-time tracking and investigate the biodistribution of the delivered MSCs.

Protocol

All procedures involving animals in this protocol were approved by the Institutional Animal Care and Use Committee, with the approval of the Ethics Committee for animal use in Taipei Medical University (approval no. LAC-2018-0574; 15.03.2019).
1. Labeling of MSCs with SPIO Nanoparticles

1. To label MSCs with SPIO, add 6 mL of labeling media (25 µg/mL of SPIO in Dulbecco’s modified Eagle medium [DMEM] with no fetal bovine serum [FBS]) to a T75 flask containing MSCs (80% confluency).

2. Incubate the cells with the labeling media in a CO₂ incubator (37 °C, 5% CO₂) without shaking. After 24 h, gently remove the labeling media using a sterile Pasteur pipette with a plastic tip attached to a vacuum. Wash the cells monolayer 2x with 6 mL of phosphate buffered saline (PBS) to remove any traces of uninternalized SPIO.

   1. To determine whether the cells have been successfully labeled, check the labeled cells under a fluorescent microscope or confocal microscope if the SPIO are tagged with a fluorophore (i.e., like those used here; Figure 1B,C). Alternatively, perform Prussian blue staining for the cells (see steps 6.2–6.4 for the staining protocol).

3. Harvest adherent cells by treatment with 3 mL of trypsin and incubate at 37 °C. After 5 min of incubation, add 7 mL of pre-warmed DMEM media with 10% FBS (v/v) to inactivate the trypsin. Collect the cell suspension using a pipette into a 15 mL conical tube.

   NOTE: The cell pellet of the labeled cells will appear as a dark color due to iron loading (Figure 1D). This protocol is relevant for MSC labeling and MRI imaging. The procedure for MSC labeling¹ has been previously optimized, and only the steps to prepare labeled MSCs to track in vivo are included here, since in vivo tracking is the focus. The protocol for culturing and labeling of other cell types should be optimized by the researcher.

4. Centrifugate the cell suspension at 300 x g for 5 min. Discard the supernatant and resuspend the cell pellet in PBS. Count the viable cells using trypan blue dye and a hemocytometer.

   NOTE: The skull sutures and both bregma and lambda can now be easily identified.

5. Adjust the cell concentration using PBS to 150,000 cells (or a number that results in a sufficient MRI signal) in 18 µL of PBS (or the total volume that will be used in the intranasal delivery procedure).

   NOTE: It was noticed that a cell concentration higher than 150,000 cells/18 µL of PBS leads to cell aggregation, which may affect the efficiency of intranasal delivery. If a higher number of cells is needed for intranasal delivery, increase the total volume of cell suspension and increase the number of intranasal administrations, as intranasal administration is a non-invasive procedure, and multiple dosing is possible.

2. Controlled Cortical Impact (CCI) Injury

   NOTE: In this protocol, male C57 BL/6 mice (7–8 weeks old) were kept in a 12/12 h light/dark cycle with ad libitum access to food and water.

1. To prepare each mouse for CCI injury, administer the zolazepam (50 mg/kg) and xylazine (20 mg/kg) anesthetizing cocktail via intraperitoneal (i.p.) injection (1 mL/kg). Ensure that the depth of anesthesia is sufficient by a lack of toe-pinch response. Alternatively, place the mouse in a chamber supplied with 2%–4% isoflurane for 60 s.

2. Shave the fur of the dorsal surface of the skull between the ears using an electronic hair clipper. Clean the shaved area several times using a sterile cotton swab soaked in 3% H₂O₂.

3. Place the anesthetized mouse in the stereotactic frame and secure the mouse using ear bars and nose bars. Make a midsagittal incision through the bone may cause damage to the brain parenchyma. Clean bone dust away using a clean and dry cotton swab.

4. Remove the tissue on the bone using a cotton pad to expose the skull. Clean the skull surface using a cotton swab soaked in 70% ethanol to clean off the iodine.

5. Adjust the coordinates of choice on the skull surface for the CCI injury and draw a circle (4 mm diameter) around the coordinates using a pencil or proper marker.

   NOTE: In this protocol, the coordinates at anteroposterior (AP) -2.0 mm and mediolateral (ML) +1.5 mm were used for CCI induction.

6. Use a microdrill and round burr (0.5 mm diameter) to thin the skull at the marked circle. Avoid applying pressure while drilling, as drilling through the bone may cause damage to the brain parenchyma. Clean bone dust away using a clean and dry cotton swab.

7. Gently remove the bone flap using sterile forceps to expose the dura mater while keeping it intact. Remove the mouse from the stereotactic frame and secure the mouse using ear bars and nose bars. Make a mid sagittal incision (approximately 2.5 cm) in the shaved skin using sterile scissors to access the surface of the skull.

8. Remove the tissue on the bone using a cotton pad to expose the skull. Clean the skull surface using a cotton swab soaked in a 3% H₂O₂ for 10 s, then clean it with a dry cotton pad.

   NOTE: The skull sutures and both bregma and lambda can now be easily identified.

9. Identify the coordinates of choice on the skull surface for the CCI injury and draw a circle (4 mm diameter) around the coordinates using a pencil or proper marker.

   NOTE: In this protocol, the coordinates at anteroposterior (AP) -2.0 mm and mediolateral (ML) +1.5 mm were used for CCI induction.

10. Use a microdrill and round burr (0.5 mm diameter) to thin the skull at the marked circle. Avoid applying pressure while drilling, as drilling through the bone may cause damage to the brain parenchyma. Clean bone dust away using a clean and dry cotton swab.

11. Gently remove the bone flap using sterile forceps to expose the dura mater while keeping it intact. Remove the mouse from the stereotactic frame that was used for pre-injury preparation and place it into the stereotactic frame of the CCI device.

12. Stabilize the head of the mouse using the ear bars and nose bars. Make sure the head of the mouse is level in the rostral-caudal direction and adjust the nose bars, if needed.

13. Follow the instructions on the control box to zero the impactor tip to the exposed cortical surface. Make sure that the impactor tip is aligned directly above the desired cortex coordinates to be impacted using the X and Y control wheels on the base of the impactor.

14. Set the experiment parameters using the control box with a velocity of 5 m/s, dwell time of 250 ms, and injury depth of 1 mm to induce mild injury in the mouse.

15. Induce injury by pressing the “impact” button on the control box. Swab any bleeding that occurs using a sterile cotton swab.

16. Remove the mouse from the stereotactic frame and close the incision using silk surgical sutures. Do not use metal clips to close the surgical site, since the mouse will be subjected to a magnetic field for MRI.

17. Apply topical antibiotics (bacitracin neomycin) to the surgical site to prevent infections. Keep the mouse on the heating pad and monitor it closely during the recovery phase.

18. Administer ketoprofen (2.5 mg/kg, IP) daily for 3 days after surgery, unless the ketoprofen administration contradicts with the study goals.

3. Intranasal Delivery

1. At 1 day post-CCI induction, administer the zolazepam (50 mg/kg) and xylazine (20 mg/kg) anesthetizing cocktail via i.p. injection. Ensure that the mouse is deeply anesthetized by lack of toe-pinch response.

2. Prepare the mouse for intranasal delivery of MSCs by hyaluronidase treatment.

   1. Grab the mouse’s scruff and turn on its back firmly while immobilizing the skull. Place the tip of a pipette that contains hyaluronidase in sterile PBS (4 U/µL) near the nostril of the mouse at a 45° angle.
2. Administer 3 μL of hyaluronidase suspension in each nostril. Keep the mouse immobilized and facing upward on a clean pad for 5 min. Repeat hyaluronidase treatment 4x (total of 100 U hyaluronidase suspension).

3. After hyaluronidase treatment, keep the treated mouse on a clean pad facing up for 30 min.

4. To deliver MSCs into the brain, hold the mouse firmly, as described in step 3.2.1. Administer 3 μL/nostril of MSC suspension with a 3 s interval. Keep holding the mouse in the same position for 30 s until the sample drops have completely disappeared.

   NOTE: Avoid forming air bubbles during administration.

5. Repeat the administration with a 2 min interval up to 3x.

   NOTE: The total number of cells to be delivered is 150,000, such that 18 μL of the cell suspension can be delivered at a 3 μL dosage for each nostril, 3x each.

6. Return the mouse to its cage and monitor it closely until it fully recovers from anesthesia.

4. In Vivo Magnetic Resonance Imaging

   NOTE: Histological staining of brain tissue has previously been used to confirm the successful delivery of stem cells after intranasal administration. However, this method can only be used as an endpoint of a study, not longitudinally. Using MRI probes to label therapeutic stem cells will allow for longitudinal, non-invasive, in vivo tracking of the cells using MRI. Importantly, this protocol efficiently reduces the number of animals required. In this protocol, MRI scanning was performed at days 1, 7, and 14 post-delivery of MSCs.

   1. To prepare the mouse for MRI scanning, anesthetize the mouse with isoflurane (5% isoflurane in 1 L/min of O₂ for induction, 1.5%–2% isoflurane for maintenance). Perform a toe-pinch to ensure that the mouse reaches the required anesthesia level.

   2. Place the mouse on the imaging holder and secure its position using taps or any other proper method. Move the holder to the center of the MRI coil (7 T/40 cm magnet) and connect the monitoring connection.

   3. To acquire T2* - weighted scans using a spin-echo sequence, set the repetition time (TR) to 1500 ms and echo time (TE) to 2.8 ms.

   4. Use a 16 mm x 16 mm field of view (FOV), 128 x 128 acquisition matrix (MTX), and slice thickness of 0.75 x 0.8 mm³ with four signal averages and a 90° flip angle (FA).

   5. Retract the mouse holder from the MRI coil center after completing the scans. Return the mouse to its cage and monitor it closely until it completely recovers from anesthesia.

   6. To track and quantify the labeled MSCs on the T2*-weighted images, use ITK-SNAP software (version 3.8.0)⁷.

      1. Transfer the raw data of the MRI scans from the MRI machine’s computer to the computer used for analysis in a DICOM (digital imaging and communications in medicine) format.

      2. Run the ITK-SNAP software and load the MRI images by clicking on the File button. Then, click on Open Main Image in the menu. Press on the Open Image button in the display window, then locate and open the MRI images using the Browse button.

      3. Create segmentations of the hypointense areas and lesion or other brain parts by selecting Active Label in the segmentation labels section. Use different label colors for different segments (if the segmentation of more than one part is needed).

      4. Use the Polygon tool in the Main Toolbar to draw around the hypointense areas representing the SPIO-labeled MSCs. Select Accept, located below the MRI image. The segmented areas will appear as the same color of the active label assigned to that particular segment. Repeat this segmentation step for all MRI slices.

      5. Develop a 3D map of the segmented areas to represent the MSC distribution in the whole brain by selecting the Scalpel Tool at the bottom of the 3D Toolbar, located in the Segmentation Labels section at the bottom of theITK-SNAP toolbox. Then, press Accept at the bottom of the created 3D map.

      6. To perform a quantitative analysis (volume and intensity mean) of the segmented hypointense areas representing labeled cells, press the Segmentation button in the top panel and select Volume and Statistics.

5. Fixation of the Mouse Brain and Cryosectioning

   1. To fix the mouse brain, perform transcardiac perfusion with 4% paraformaldehyde (PFA) following the last MRI scan, as previously described⁸.

      1. Decapitate the head and extract the brain⁹. Fix the brain with 4% PFA for at least 48 h at 4 °C.

      2. Dehydrate the brain by immersing it into a 30% sucrose solution at 4 °C until the brain sinks to the bottom of the solution.

   2. Embed the brain in the optimal cutting temperature (OCT) solution and freeze at -20 °C. Section the brain with a cryostat microtome into slices with 14 μm thickness and mount them onto slides. Store the sections slides at -20 °C until further use.

6. Prussian Blue Staining

   NOTE: Prussian blue staining is commonly used to detect the iron content in SPIO-labeled cells. Here, Prussian blue staining is used to confirm that the hypointense signals in the MRI images correspond to the SPIO-labeled MSCs and not to artifacts. Prussian blue staining is one of the most sensitive histochemical methods used to detect iron in tissues and can be used to identify even a single granule of iron in the cells.

   1. Wash the slides of brain sections with distilled water for 5 min.

   2. Perform Prussian blue staining by immersing the slides for 30 min in the staining solution, which contains equal parts hydrochloric acid (10%) and potassium ferrocyanide (10%) prepared immediately before use.

   3. Wash 3x with distilled water, for 5 min each. Counterstain the sections with nuclear fast red for 5 min. Rinse the slides 2x with distilled water.

   4. Dehydrate the sections gradually by immersing the slides in 95% and 100% alcohol for 2 min each. Add coverslip with a resinous mounting medium.
5. Use a light microscope to detect the stained cells in the brain sections.

**NOTE:** The iron in the labeled cells will appear as blue colored deposits.

### Representative Results

Twenty-four hours following intranasal delivery, the SPIO-labeled MSCs were detected as strong hypointense areas medial to the cortical injury on T2*–weighted images (Figure 2B), indicating the targeted migration of SPIO to the injury site. This migration remained visible up to 14 days post-delivery, as the hypointense signals were found to be visible without significant reduction for this time period (Figure 2B). The injured animals treated with PBS showed no hypointense areas, indicating that the observed hypointense areas correspond to the SPIO labeled MSCs and not to signal artifacts (Figure 2A). The biodistribution of the labeled MSCs that were observed in vivo with MRI was visualized using 3D reconstruction (Figure 2C,D). The migration of MSCs to the injured cortex was confirmed histologically by Prussian blue staining and FITC channel detection of the FITC-tagged SPIO in the labeled MSCs (Figure 3A,B).

![Figure 1: Schematic flowchart of the protocol and in vitro confirmation of SPIO uptake by MSCs. (A) MSCs were incubated with SPIO for 24 h for labeling. Then, the labeled MSCs were delivered into a TBI mouse model via an intranasal (IN) route. MRI at different timepoints was performed to track the labeled MSCs. Confirmation of sufficient labeling of MSCs by SPIO was achieved by (B) fluorescence microscopy and (C) confocal microscopy using the FITC channel, since SPIO nanoparticles were tagged with FITC. (D) The cell pellet of the labeled MSCs appeared dark in color due to iron loading. FITC = fluorescein isothiocyanate; SPIO = superparamagnetic particles of iron oxide; MSCs = mesenchymal stem cells; MRI = magnetic resonance imaging; IN = intranasal; TBI = traumatic brain injury. Please click here to view a larger version of this figure.](image-url)
Figure 2: Real-time MRI enables the detection and tracking of SPIO-labeled MSC migration toward injury sites in the brains of TBI-induced mice. (A) Mice were subjected to TBI, followed by treatment with PBS or SPIO-labelled MSCs, administered via an intranasal route 24 h after injury. Coronal sections of T2*-weighted images showed the labeled MSCs as a hypointense area (arrowhead) on the edge of the injury site (outlined area) at 1, 7, and 14 days post-delivery. The PBS-treated mice show no hypointense area. (B) Segmentation process of the injury site area (green) and labeled MSCs (red) based on coronal T2*-MRI images. (C) 3D reconstruction of the mouse brain treatment based on T2*-weighted images illustrating the biodistribution of SPIO-labeled MSCs in the brain 14 days post-delivery. Please click here to view a larger version of this figure.
Figure 3: Histological analysis confirms the presence of SPIO-labeled MSCs in the brains of the treated animals. Prussian blue staining of brain sections of a (A) mouse treated with PBS (control) and (C) mouse treated with SPIO-labeled MSCs. SPIO-positive cells were detected in MSC-treated mouse (boxed cells, blue), while the control mouse showed no positive cells at the injury site in the cortex at 14 days post-delivery, confirming MRI observations. Fluorescence microscopy analysis of the cortex of a (B) control mouse treated with PBS and (D) mouse treated with SPIO-labeled MSCs was conducted 14 days post-delivery. The analysis revealed the presence of FITC-tagged SPIO-positive cells (boxed cells, green) at the injured cortex in the MSC-treated mouse, but no FITC signals were observed in the cortex of the PBS-treated mouse. Scale bars = 50 µm, unless stated otherwise. Please click here to view a larger version of this figure.

Discussion

The protocol described here represents general procedures for the SPIO labeling of MSCs and MRI tracking of SPIO-labeled MSCs post-intranasal delivery. The protocol allows the opportunity to study the migration and biodistribution of MSCs post-delivery in vivo in the brain, using a non-invasive method.

MSCs are attractive candidates for stem cell-based therapies for CNS disorders and injuries due to their ability to secrete trophic factors that 1) trigger neurorestorative processes and 2) provide neuroprotection, owing to their anti-inflammatory effects within the injury area. Long-term MRI tracking and detection of SPIO-labeled MSCs may be limited due to the dilution of intercellular SPIO with cell division, labeled cells can be detected for up to several weeks post-transplantation in the brains of animal models.

Also described here is the labeling protocol of MSCs with SPIO nanoparticles coated with dextran without transfection agents. Other protocols have been used in the literature. However, in all cases, these protocols should be adjusted for cell type, SPIO size, incubation time, and SPIO concentration. MSCs have been shown to have impaired chondrogenic differentiation potential but not adipogenic differentiation upon SPIO labeling. Therefore, it is highly recommended that differentiation assays be performed prior to stem cell delivery to evaluate the influence of SPIO on the differentiation potency of stem cells. In a previous study, it was demonstrated that MSC labeling with the same SPIO type and concentration used in the here did not affect the osteogenic or adipogenic differentiation potency of MSCs.

The intranasal route of therapeutic stem cell delivery for brain disorders and injuries is a promising approach for the clinical application of stem cells. However, the intrinsic and molecular mechanisms that dictate the behaviors of stem cells in the nasal cavity remain unclear. Although the intranasal route is widely explored for the delivery of small molecules, the size and biodistribution behavior of the therapeutic stem differ from small molecules. The current protocol demonstrates that MSCs tend to migrate toward the injury site after intranasal delivery.

Here, T2*-weighted images were used to track the SPIO-labeled MSCs. Other reports have used gradient echo imaging. However, susceptibility artefacts are often observed in gradient echo imaging due to intercellular SPIO. In the current protocol, the location of the hypointense areas representing the SPIO-labeled MSCs on T2*-weighted images was the same as the location of the SPIO in brain sections as detected by histological examination. This indicates the adequate sensitivity of T2*-weighted spin echo imaging for SPIO-labeled MSC tracking in the brain.

In summary, the described protocol is beneficial for in vivo stem cell tracking studies of brain injuries and disorders. The longitudinal tracking of stem cells in vivo has traditionally been performed by sacrificing animals at multiple timepoints. The current protocol provides a non-invasive and efficient approach for MSCs delivery and tracking, which represents a potential procedure for stem cell-based therapy for brain injuries and disorders in clinical settings.
Disclosures

The authors have nothing to disclose.

Acknowledgments

This work was supported by the Ministry of Science and Technology Grants, Taiwan (MOST 104-2923-B-038-004-MY2, MOST 107-2314-B-038-063, and MOST 107-2314-B-038-042) and Taipei Medical University (TMU 105-AE1-B03, TMU 106-5400-004-400, TMU 106-5310-001-400, DP2-107-21121-01-N-05 and DP2-108-21121-01-N-05-01).

References